BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29669354)

  • 1. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
    Tursi A; Franceschi M; Allegretta L; Savarino E; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Scida S; Miraglia C; Penna A; Licci C; Rizzo GL; Pranzo G; Cassieri C; Brandimarte G; Picchio M; Di Mario F
    Dig Dis; 2018; 36(4):264-268. PubMed ID: 29669354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.
    Gómez Rodríguez BJ; Castro Laria L; Argüelles Arias F; Castro Márquez C; Caunedo Álvarez Á; Romero Gómez M
    Rev Esp Enferm Dig; 2017 Aug; 109(8):552-558. PubMed ID: 28617030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains.
    Muller N; Amiot A; Le Thuaut A; Bastuji-Garin S; Deforges L; Delchier JC
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):517-24. PubMed ID: 26850363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the use of quadruple therapy with bismuth (Pylera
    Agudo-Fernández S; González Blanco A
    Gastroenterol Hepatol; 2018 Oct; 41(8):483-489. PubMed ID: 30041999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice.
    Pérez-Arellano E; Rodriguez-Garcia MI; Galera Rodenas AB; de la Morena-Madrigal E
    Gastroenterol Hepatol; 2018 Mar; 41(3):145-152. PubMed ID: 29054320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
    Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
    Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies.
    Ciccaglione AF; Cellini L; Marzio L
    Helicobacter; 2019 Oct; 24(5):e12606. PubMed ID: 31168941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
    Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
    Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
    Rodríguez de Santiago E; Martín de Argila de Prados C; Marcos Prieto HM; Jorge Turrión MÃ; Barreiro Alonso E; Flores de Miguel A; de la Coba Ortiz C; Rodríguez Escaja C; Pérez Álvarez G; Ferre Aracil C; Aguilera Castro L; García García de Paredes A; Rodríguez Pérez A; Albillos Martínez A
    Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28771880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
    Dore MP; Bibbò S; Loria M; Salis R; Manca A; Pes GM; Graham DY
    Helicobacter; 2019 Dec; 24(6):e12659. PubMed ID: 31502382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
    Wang Z; Wu S
    Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
    Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.